Ask about this productRelated genes to: RASL12 antibody
- Gene:
- RASL12 NIH gene
- Name:
- RAS like family 12
- Previous symbol:
- -
- Synonyms:
- RIS
- Chromosome:
- 15q22.31
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-03
- Date modifiied:
- 2016-10-05
Related products to: RASL12 antibody
Related articles to: RASL12 antibody
- Lung adenocarcinoma (LUAD) poses significant clinical challenges due to its heterogeneity and metastatic potential, necessitating deeper molecular characterization. This study investigated the role of miR-6791-5p and its target RASL12 in LUAD progression. - Source: PubMed
Publication date: 2026/07/25
Zhang LuPang ZhonghaoZhang HaiboWang Pin - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited diagnostic tools and therapeutic options. Dysregulated mitophagy in astrocytes plays a pivotal role in AD pathogenesis. This study aims to identify a mitophagy and astrocyte (MA)-associated molecular signature for AD diagnosis and therapeutic targeting. - Source: PubMed
Publication date: 2026/07/24
Liu JiachengChen Wei - Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by aberrant fibroblast activation and excessive extracellular matrix (ECM) accumulation, resulting in irreversible lung remodeling. Although fibroblasts are central to IPF pathogenesis, comprehensive transcriptomic analyses of IPF patient-derived lung fibroblasts remain limited. This study aimed to identify novel molecular contributors to IPF through transcriptomic profiling of lung fibroblasts. - Source: PubMed
Publication date: 2026/03/27
Seo Eun-JeongLee Jong-UkPark Seung-LeeKim Min-KyungChoi Jae-SungHwang Hun-GyuKim Jung-HyunChang Hun-SooPark Choon-Sik - Aberrant proliferation of mesangial cells (MCs) is a central driver of glomerular injury in IgA nephropathy (IgAN) and lupus nephritis (LN), the two most common mesangioproliferative glomerulopathies. Emerging evidence implicates dysregulated arginine-proline metabolism in this process; however, the key regulatory genes and underlying mechanisms remain incompletely defined. Here, we performed integrative bulk RNA sequencing of glomerular datasets and applied machine learning algorithms (LASSO and SVM-RFE) to identify disease-specific differentially expressed genes (DEGs) linked to the arginine-proline metabolic pathway. We identified 34 LN-specific and 18 IgAN-specific DEGs, among which ASS1, PCK1, and CBR3 emerged as core hub genes through feature selection and network analyses. A nomogram-based diagnostic model incorporating these genes demonstrated strong predictive performance, with AUC values exceeding 0.75 in internal cohorts and robust validation across external datasets. Single-cell RNA sequencing of mouse models delineated seven MC subclusters, highlighting Rasl12 and Col3a1 subpopulations with pronounced proliferative-inflammatory phenotypes, characterized by downregulated ASS1 and PCK1 and upregulated CBR3. These transcriptional patterns were corroborated in vivo in anti-Thy1 nephritis rats, BAFF-transgenic IgAN mice, and MRL/lpr LN mice, where altered gene expression correlated with mesangial hyperplasia, macrophage infiltration, and elevated inflammatory cytokines. Functional assays in PDGF-BB-stimulated human MCs further demonstrated that overexpression of ASS1 or PCK1, or knockdown of CBR3, attenuated MC activation, proliferation, and proinflammatory crosstalk with macrophages. Collectively, our results position ASS1, PCK1, and CBR3 as pivotal regulators of arginine-proline metabolism in mesangial proliferation, establishing them as innovative diagnostic biomarkers and therapeutic targets for precise management of IgAN and LN. - Source: PubMed
Publication date: 2025/12/04
He JiayiPeng FeiQu YilunZhao YinghuaLi YueyangZhou YueranGuo ChangLi XingangSong MansuChen XiangmeiHong QuanWang Wei - Cancer-associated fibroblasts (CAFs) play a critical role in hepatocellular carcinoma (HCC) progression. This study aimed to develop a CAF-based risk signature model for predicting prognosis and identifying potential therapeutic targets. - Source: PubMed
Publication date: 2025/10/24
Qian WenchenWu KezhiShen ZhuNi BowenZheng HaojieLiu YaweiGuo Manlan